Asarina Pharma: Publication of PMDD Phase IIb study - Redeye
Bildkälla: Stockfoto

Asarina Pharma: Publication of PMDD Phase IIb study - Redeye

The scientific journal Psychoneuroendocrinology recently published data of Asarina Pharma’s phase IIb study in Sepranolone for PMDD (Premenstrual dysphoric disorder), showcasing ‘significant treatment effect’.

Börsvärldens nyhetsbrev
ANNONSER